beta-hydroxyisovaleryl shikonin, 7415-78-3

Articles:

PubMed:	Anti-inflammatory effects of β-hydroxyisovalerylshikonin in BV2 microglia are mediated through suppression of the PI3K/Akt/NF-kB pathway and activation of the Nrf2/HO-1 pathway.
PubMed:	Retraction notice to "β-Hydroxyisovalerylshikonin has a profound anti- growth activity in human endometrial and ovarian cancer cells" [Gynecol. Oncol. 109 (2008) 107-114].
PubMed:	In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanoma.
PubMed:	Naphthoquinones from Onosma paniculata induce cell-cycle arrest and apoptosis in melanoma Cells.
PubMed:	Synthesis and antitumour activity of β-hydroxyisovalerylshikonin analogues.
PubMed:	Anti-neoplastic effect of β-hydroxyisovalerylshikonin on a human choriocarcinoma cell line.
PubMed:	Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin.
PubMed:	Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
PubMed:	A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity.
PubMed:	Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon.
PubMed:	Beta-hydroxyisovalerylshikonin induces apoptosis and G0/G1 cell-cycle arrest of endometriotic stromal cells: a preliminary in vitro study.
PubMed:	Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin.
PubMed:	[Basic studies for the development of anticancer, antidementia, and taste modifier drugs].
PubMed:	Beta-hydroxyisovalerylshikonin and cisplatin act synergistically to inhibit growth and to induce apoptosis of human lung cancer DMS114 cells via a tyrosine kinase-dependent pathway.
PubMed:	A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases.
PubMed:	Beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases.
PubMed:	Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
PubMed:	Synergistic inhibitory effects of transplatin and beta-hydroxyisovalerylshikon on carcinoma A431 cells involve epidermal growth factor receptor.
PubMed:	Shikonin production by p-fluorophenylalanine resistant cells of Lithospermum erythrorhizon.
PubMed:	Physical stability of shikonin derivatives from the roots of Lithospermum erythrorhizon cultivated in Korea.
PubMed:	beta-hydroxyisovalerylshikonin inhibits the cell growth of various cancer cell lines and induces apoptosis in leukemia HL-60 cells through a mechanism different from those of Fas and etoposide.